Insilico Medicine Initiates First-in-Human Study

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055. Read more in PR Newswire.